Non-small cell lung cancer (NSCLC) accounts for about 80–85% of all lung cancers424 and about 20% of NSCLC report alterations in LKB1 (Liver Kinase B1).425 It has been reported that LKB1-deficient NSCLC (LKBC) is associated with aberrant dephosphorylation and activation of the transcriptional co-activator CRTC2. Here, STK11 is linked to non-small cell lung carcinoma.